Liminal BioSciences is a global clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases with a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada,  and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market (LMNL).

On October 15, 2021 the Company closed on the divestment of the remainder of its plasma-derived therapeutics business to focus solely on its small molecule therapeutics pipeline.

 

Subscribe here to receive Liminal's latest news by email.     

Investor Resources

 

 

 

Contact Us →

Recent News
Aug 9, 2022
Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights

$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras development Net loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared...

Jul 21, 2022
Liminal BioSciences Announces Discontinuation of Fezagepras Development

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") today announced that it has discontinued development of fezagepras. The decision to discontinue the development of...

Jun 6, 2022
Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of Shareholders ("AGM") held virtually on June 6,...

Webcasts
Q2 2022 Results Conference Call
Wednesday, August 10, 2022
8:30am - 9:30am EDT
Jefferies Investor Conference
Thursday, June 9, 2022
2:00pm EDT
Stock Quote
NASDAQLMNL